Blue Jay Capital Management
Latest statistics and disclosures from Blue Jay Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Tesaro, Clovis Oncology, INCY, IRWD, Wright Medical Group Nv, and represent 30.98% of Blue Jay Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Qiagen Nv (+$7.3M), SNN (+$7.0M), Portola Pharmaceuticals (+$6.7M), NBIX (+$6.7M), BKD (+$6.6M), ICLR (+$6.2M), ALGN (+$5.1M), ILMN, ISRG, Wright Medical Group Nv.
- Started 9 new stock positions in ISRG, BKD, ILMN, SNN, Portola Pharmaceuticals, ICLR, NBIX, ALGN, Qiagen Nv.
- Reduced shares in these 10 stocks: , GMED (-$12M), , BMY (-$11M), C.R. Bard (-$9.3M), NuVasive (-$9.2M), Celgene Corporation (-$9.1M), , Akorn (-$7.2M), Dermira (-$7.2M).
- Sold out of its positions in Akorn, MDRX, C.R. Bard, BIIB, BMY, Celgene Corporation, Dermira, GMED, NuVasive, Qiagen.
- Blue Jay Capital Management was a net seller of stock by $-64M.
- Blue Jay Capital Management has $147M in assets under management (AUM), dropping by -27.85%.
- Central Index Key (CIK): 0001586444
Tip: Access up to 7 years of quarterly data
Positions held by Blue Jay Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Blue Jay Capital Management
Blue Jay Capital Management holds 20 positions in its portfolio as reported in the June 2017 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Tesaro | 6.4 | $9.4M | -20% | 68k | 139.86 |
|
Clovis Oncology | 6.3 | $9.3M | -33% | 99k | 93.63 |
|
Incyte Corporation (INCY) | 6.2 | $9.1M | +3% | 72k | 125.91 |
|
Ironwood Pharmaceuticals (IRWD) | 6.0 | $8.9M | -30% | 470k | 18.88 |
|
Wright Medical Group Nv | 6.0 | $8.8M | +4% | 320k | 27.49 |
|
BioMarin Pharmaceutical (BMRN) | 5.8 | $8.6M | -10% | 95k | 90.82 |
|
Pra Health Sciences | 5.5 | $8.0M | -23% | 107k | 75.01 |
|
Edwards Lifesciences (EW) | 5.4 | $8.0M | -25% | 67k | 118.25 |
|
Abiomed | 5.4 | $7.9M | -26% | 55k | 143.30 |
|
Nevro (NVRO) | 5.3 | $7.8M | +5% | 105k | 74.43 |
|
Qiagen Nv | 5.0 | $7.3M | NEW | 218k | 33.53 |
|
Smith & Nephew (SNN) | 4.8 | $7.0M | NEW | 200k | 34.85 |
|
Portola Pharmaceuticals | 4.6 | $6.7M | NEW | 120k | 56.17 |
|
Neurocrine Biosciences (NBIX) | 4.5 | $6.7M | NEW | 145k | 46.00 |
|
Brookdale Senior Living (BKD) | 4.5 | $6.6M | NEW | 450k | 14.71 |
|
Icon (ICLR) | 4.2 | $6.2M | NEW | 63k | 97.79 |
|
Vertex Pharmaceuticals Incorporated (VRTX) | 4.1 | $6.0M | -42% | 46k | 128.87 |
|
Align Technology (ALGN) | 3.5 | $5.1M | NEW | 34k | 150.13 |
|
Illumina (ILMN) | 3.2 | $4.8M | NEW | 28k | 173.53 |
|
Intuitive Surgical (ISRG) | 3.2 | $4.7M | NEW | 5.0k | 935.40 |
|
Past Filings by Blue Jay Capital Management
SEC 13F filings are viewable for Blue Jay Capital Management going back to 2014
- Blue Jay Capital Management 2017 Q2 filed Aug. 11, 2017
- Blue Jay Capital Management 2017 Q1 filed May 12, 2017
- Blue Jay Capital Management 2016 Q4 filed Feb. 13, 2017
- Blue Jay Capital Management 2016 Q3 filed Nov. 10, 2016
- Blue Jay Capital Management 2016 Q2 filed Aug. 12, 2016
- Blue Jay Capital Management 2016 Q1 filed May 13, 2016
- Blue Jay Capital Management 2015 Q4 filed Feb. 12, 2016
- Blue Jay Capital Management 2015 Q3 filed Nov. 13, 2015
- Blue Jay Capital Management 2015 Q2 filed Aug. 13, 2015
- Blue Jay Capital Management 2015 Q1 filed May 13, 2015
- Blue Jay Capital Management 2014 Q4 filed Feb. 13, 2015